Adocia S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADOC.PA research report →
About the company
Adocia S. A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders.
- CEO
- Olivier Soula
- IPO
- 2012
- Employees
- 76
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $79.13M
- P/E
- -4.13
- P/S
- 53.65
- P/B
- 52.63
- EV/EBITDA
- -4.61
- Div Yield
- 0.00%
- Gross Margin
- -1213.97%
- Op Margin
- -1229.56%
- Net Margin
- -1124.81%
- ROE
- -3796.57%
- ROIC
- -142.92%
- Revenue
- $1.48M · -84.17%
- Net Income
- $-16,591,000 · -78.00%
- EPS
- $-0.85 · -41.67%
- Op Income
- $-18,136,000
- FCF YoY
- 57.09%
- 52W High
- $12.40
- 52W Low
- $3.58
- 50D MA
- $4.66
- 200D MA
- $6.48
- Beta
- 0.28
- Avg Volume
- 236.50K
Get TickerSpark's AI analysis on ADOC.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ADOC.PA coverage
Recent articles, reports, and earnings notes.
No research on ADOC.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADOC.PA report →Similar companies
Peers in the same neighborhood.